Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30754558 | 1.00 | TOP1 (0.32) | TOP1KRASSOS1 | |
| SCHEMBL29926474 | 0.79 | KRAS (0.48) | KRASSOS1 | |
| SCHEMBL21494905 | 0.79 | KRAS (0.48) | KRASSOS1 | |
| SCHEMBL29863061 | 0.79 | KRAS (0.33) | KRASSOS1 | |
| SCHEMBL21494875 | 0.79 | KRAS (0.33) | KRASSOS1 | |
| SCHEMBL24800366 | 0.79 | ALDH1A1 (0.35) | — | |
| SCHEMBL21494871 | 0.73 | KRAS (0.52) | KRASSOS1 | |
| SCHEMBL30878232 | 0.73 | PIK3CD (0.32) | — | |
| SCHEMBL30006963 | 0.73 | — | — | |
| SCHEMBL29926561 | 0.73 | KRAS (0.52) | KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | disclosed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-25 | — | — | US | disclosed |
| WO-2024079252-A1 | SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024056782-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-21 | — | — | WO | disclosed |
| EP-4322962-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500507-A | Phosphorus derivatives as novel SOS1 inhibitors | 拜耳公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022219035-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | SOST, PPM1D, SOS1 | TOP1 956/4885KRAS 119/4885SOS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.